Fibroid cell growth

Fibroid cell growth refers to the pathological proliferation of smooth muscle cells and fibroblasts in the uterus, which leads to the development of uterine leiomyomas, commonly known as fibroids (NIH, 2023). This growth is primarily regulated by the ovarian steroid hormones estrogen and progesterone, which act through their respective nuclear receptors to drive cell division and the accumulation of extracellular matrix (StatPearls, 2023). At the molecular level, the Progesterone Receptor (PR) is the central mediator of this growth, while the Estrogen Receptor (ER) plays a crucial permissive role by upregulating PR expression (Bulun et al., 2015). Therapeutic management of this growth involves targeting the hormonal pathways that fuel it, primarily through the use of GnRH receptor antagonists like elagolix and relugolix or selective progesterone receptor modulators (SPRMs) like ulipristal acetate (PubMed, 2022). While inhibiting this growth is the goal of medical therapy for symptomatic leiomyomas, 'Fibroid cell growth' describes a biological process and clinical endpoint rather than a single targetable molecule. Consequently, it is categorized as a disease-related physiological phenomenon rather than a canonical therapeutic target in pharmacological databases.

Other names

Uterine leiomyoma cell proliferationUterine fibroid expansionMyoma growthMyometrial cell proliferation

Inhibition of the hypothalamic-pituitary-ovarian axis to suppress ovarian steroid production or direct modulation of progesterone receptors to inhibit cellular proliferation and induce apoptosis.